Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review

Mekhail, Christine; Chouk, Mickaël; Prati, Clément; Wendling, Daniel; Verhoeven, Frank

doi:10.1080/17512433.2020.1758556

Cited by 9 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies have shown that targeted therapies are effective in this scenario (anti-TNF, anti-IL-17, anti-IL-23, JAK inhibitors) [9,[99][100][101][102][103][104][105][106][107][108][109].…”

Section: Treatment With Csdmards Should Be Considered If Nsaids Have Failed Along With Local Interventions In Cases Of Psoriasis Methotrementioning

confidence: 99%

2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis

et al. 2022

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Treatment With Csdmards Should Be Considered If Nsaids Have Failed Along With Local Interventions In Cases Of Psoriasis Methotrementioning

confidence: 99%

2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ustekinumab (IL12/23 inhibitor agent) has a similar efficiency in both normal and overweight patients, but it is indicated in mono/oligoarticular forms. Ustekinumab and apremilast (PDE inhibitor) obtained better responses in patients with low disease activity [ 118 , 121 ]. The treatment strategies for juvenile PsA are similar.…”

Section: Resultsmentioning

confidence: 99%

MRI Findings in Axial Psoriatic Spondylarthritis

et al. 2023

View full text Add to dashboard Cite

Psoriatic arthritis is a significant medical condition with a high prevalence, a wide variety of non-specific symptoms, and a high degree of overlap with other spondylarthritis disorders, particularly ankylosing spondylitis. Hence, knowledge of the magnetic resonance imaging (MRI) manifestations and a multidisciplinary strategy are required for the better management of these patients. We searched publications from the last 10 years and focused on the most relevant ones which discussed the classification criteria, the MRI characteristics of axial psoriatic arthritis, the importance of MRI for follow up, and the reliability of skin and synovial biopsy. Axial spondylarthritis can be diagnosed and followed up on using the well-established MRI technique and, additionally, a biopsy. The analysis and concordance between them can provide new directions for future studies.

show abstract

“… 59 Other factors such as uveitis, inflammatory bowel disease, erosive or rapidly progressive radiographic disease or axial involvement may be deemed higher risk for biologic withdrawal or tapering. 60 This is of particular relevance since the evidence suggests that it can be difficult to regain response to a b/tsDMARD once treatment is interrupted, for example, for infection, pregnancy or surgery. Furthermore, real-world evidence shows that responses to second-/third-/fourth-line b/tsDMARD agents are consistently reduced compared with first line.…”

Section: What Is the Best Treatment Strategy In Psa?mentioning

confidence: 99%

Early psoriatic arthritis: when is the right time to start advanced therapy?

Hen,

Harrison,

De Marco

et al. 2024

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Despite significant advances in the treatment of psoriatic arthritis (PsA) in the last two decades, remission remains elusive and there is no cure. Evidence from rheumatoid arthritis (RA) confirming enhanced response and outcome from earlier treatment intervention suggests the plausibility of the window of opportunity in the pathogenesis of RA. Yet, data are lacking in PsA. Although treatment response may be enhanced in shorter disease duration, it is unknown how this early intervention may impact long-term outcomes. Furthermore, it remains to be demonstrated whether there is a best treatment strategy and time of intervention. Crucially, the main hurdle when aiming for early treatment intervention is the ability to achieve a timely diagnosis that highlights the need to focus research efforts on characterizing the very early disease stages including the transition to PsA in the at-risk psoriasis population.

show abstract

Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review

Cited by 9 publications

References 39 publications

2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis

2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis

MRI Findings in Axial Psoriatic Spondylarthritis

Early psoriatic arthritis: when is the right time to start advanced therapy?

Contact Info

Product

Resources

About